scholarly journals Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Blood ◽  
2016 ◽  
Vol 127 (22) ◽  
pp. 2693-2700 ◽  
Author(s):  
Paul G. Richardson ◽  
Todd M. Zimmerman ◽  
Craig C. Hofmeister ◽  
Moshe Talpaz ◽  
Asher A. Chanan-Khan ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Antitumor Activity ◽  
Proteasome Inhibitor ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Phase 1 Trial ◽  
Refractory Multiple Myeloma ◽  
Treatment Regimens ◽  
Key Points

Key Points MRZ is an irreversible pan-proteasome inhibitor that has antitumor activity. Two treatment regimens were explored in a phase 1 trial in patients with RRMM.

scholarly journals Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Blood ◽  
2014 ◽  
Vol 124 (7) ◽  
pp. 1038-1046 ◽  
Author(s):  
Paul G. Richardson ◽  
Rachid Baz ◽  
Michael Wang ◽  
Andrzej J. Jakubowiak ◽  
Jacob P. Laubach ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Disease Control ◽  
Stable Disease ◽  
Proteasome Inhibitor ◽  
Phase 1 ◽  
Clinical Activity ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma ◽  
Key Points ◽  
Heavily Pretreated

Key Points Twice-weekly oral ixazomib appears tolerable, with no severe neuropathy seen to date, in heavily pretreated multiple myeloma patients. These phase 1 data suggest clinical activity including 76% stable disease or better, with durable responses and sustained disease control.

scholarly journals Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Blood ◽  
2014 ◽  
Vol 124 (7) ◽  
pp. 1047-1055 ◽  
Author(s):  
Shaji K. Kumar ◽  
William I. Bensinger ◽  
Todd M. Zimmerman ◽  
Craig B. Reeder ◽  
James R. Berenson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Proteasome Inhibitor ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points Weekly oral proteasome inhibitor ixazomib appears generally well tolerated with manageable toxicity, limited grade 1/2 neuropathy. Data show that more than 25% of 30 evaluable relapsed/refractory myeloma patients who received the MTD had clinically meaningful responses.

scholarly journals Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Blood ◽  
2013 ◽  
Vol 121 (11) ◽  
pp. 1961-1967 ◽  
Author(s):  
Paul G. Richardson ◽  
David Siegel ◽  
Rachid Baz ◽  
Susan L. Kelley ◽  
Nikhil C. Munshi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Safety And Efficacy ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points Pomalidomide with/without dexamethasone has promising activity and manageable toxicity in relapsed and refractory multiple myeloma patients.

scholarly journals Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood ◽  
2016 ◽  
Vol 128 (19) ◽  
pp. 2297-2306 ◽  
Author(s):  
Inger S. Nijhof ◽  
Laurens E. Franssen ◽  
Mark-David Levin ◽  
Gerard M. J. Bos ◽  
Annemiek Broijl ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 1 ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points REP is an active combination in MM patients refractory to lenalidomide. REP is an all-oral and generally well-tolerated regimen.

Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3056-3056 ◽  
Author(s):  
C. Mitsiades ◽  
A. Chanan-Khan ◽  
M. Alsina ◽  
D. Doss ◽  
B. Landrigan ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Phase 1 Trial ◽  
Refractory Multiple Myeloma

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma

2015 ◽  
Vol 101 (3) ◽  
pp. 286-294 ◽  
Author(s):  
Kenshi Suzuki ◽  
Michinori Ogura ◽  
Yu Abe ◽  
Tatsuya Suzuki ◽  
Kensei Tobinai ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma

scholarly journals Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Blood ◽  
2013 ◽  
Vol 122 (16) ◽  
pp. 2799-2806 ◽  
Author(s):  
Alessandra Larocca ◽  
Vittorio Montefusco ◽  
Sara Bringhen ◽  
Davide Rossi ◽  
Claudia Crippa ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Refractory Multiple Myeloma ◽  
Multicenter Phase ◽  
Key Points

Key Points Pomalidomide-cyclophosphamide-prednisone is an active combination in multiple myeloma patients who are relapsed/refractory to lenalidomide.

scholarly journals Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

2018 ◽  
Vol 59 (11) ◽  
pp. 2588-2594 ◽  
Author(s):  
Ajai Chari ◽  
Sarah Larson ◽  
Beata Holkova ◽  
Robert F. Cornell ◽  
Cristina Gasparetto ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Therapy ◽  
Phase 1 ◽  
Phase 1 Trial ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document